Table 2.
Treatment of Mycoplasma-Positive Cell Lines with Various Antibiotics.
| Mycoplasma | Cell line | Species | Tissue/cell type | Plasmocin | BM-Cyclin | Baytril | Other AB |
|---|---|---|---|---|---|---|---|
| A. laidlawii | HELA | Human | Cervix carcinoma | C | C | ||
| KYAE-1 | Human | Esophagus adenocarcinoma | C | C | |||
| Mz-ChA-1 | Human | Gall bladder | C | C | C | ||
| Mz-ChA-2 | Human | Gall bladder | C | C | R | ||
| PLT-2 | Human | Leukemia | R → C | C | |||
|
| |||||||
| M. arginini | A-431 | Human | Epidermoid carcinoma | C | C | C (MycoZap) | |
| BL-100 | Human | Lymphoma | C | C | C | ||
| Cell line 1 | Syrian hamster | Embryo fibroblasts | C | C | |||
| Cell line 3 | Mouse | Hybridoma | C | ||||
| MYL | Human | Leukemia | R | C | R | ||
| TA-5 | Mouse | Hybridoma | C | R | C (MycoZap) | ||
|
| |||||||
| M. arginini + M. fermentans | JEKO-1 | Human | Lymphoma | D | C | ||
|
| |||||||
| M. fermentans | CAL-1 | Human | Leukemia | C | C | D | |
| EB-3 | Human | Lymphoma | C | C | C (MycoZap) | ||
| FPR2+HL60 | Human | Leukemia | C | C | C | C (Ciprobay) | |
| HBL-2 | Human | Lymphoma | C | C | C | ||
| JOK-1 | Human | Lymphoma | C | D | C | ||
| KOPN-K | Human | Leukemia | D | D | C | ||
| LAN-6 | Human | Neuroblastoma | C | C | C | ||
| NALM-16 | Human | Leukemia | C | C | |||
| NBL-S | Human | Neuroblastoma | C | C | |||
| NCEB-1 | Human | Lymphoma | C | C | R | ||
| NK-9 | Human | Leukemia | C | C | C (MycoZap) | ||
| RAMOS | Human | Lymphoma | D → C | C | |||
| RI-1D | Human | Lymphoma | C | C | C | ||
| SACHI | Human | Leukemia | R → C | C | R | R (MRA) | |
| SKK-1 | Human | Leukemia | C | C | C | ||
|
| |||||||
| M. fermentans + M. hyorhinis | DND-39 | Human | Lymphoma | C | D | ||
|
| |||||||
| M. fermentans + M. orale | LS | Human | Neuroblastoma | C | C | C | |
|
| |||||||
| M. hyorhinis | B6 | Pig | Intestinal cells | D | C | ||
| B10XI | Pig | Intestinal cells | C | C | C | ||
| Cell line 4 | Mouse | Hybridoma | C | ||||
| Cell line 5 | Mouse | Hybridoma | C | ||||
| Cell line 6 | Mouse | Hybridoma | C | C | |||
| CIEB | Calf | Colon | R | C | R | ||
| CLAB | Pig | Colon | R | C | R | ||
| HBL-2 | Human | Lymphoma | C | C | C | ||
| HEK-293 | Human | Embryo kidney | C | C | C | ||
| MEF clone 1 | Mouse | Embryo fibroblasts | C | R | C | ||
| MEF clone 2 | Mouse | Embryo fibroblasts | C | R | C | ||
| MEL-IM | Human | Melanoma | R | C | R | ||
| PANC-02 | Mouse | Pancreas carcinoma | R | C | R | ||
| PC-12 clone 1 | Rat | Pheochromocytoma | C | C | C | ||
| PC-12 clone 2 | Rat | Pheochromocytoma | C | C | C (Ciprobay) | ||
| PC-MDS | Human | Leukemia | C | C | C | ||
| PSI | Pig | Colon | R | C | R | ||
| SVG-A | Human | Glial cells | C | C | C | ||
| WSU-DLCL-2 | Human | Lymphoma | R → C | R | R (MRA) | ||
|
| |||||||
| M. orale | Cell line 2 | Syrian hamster | Embryo fibroblasts | C | C | ||
| GI-ME-N | Human | Neuroblastoma | C | C | |||
| H-1963 | Human | Non-small-cell lung carcinoma | C | C | |||
| HCC-44 | Human | Non-small-cell lung carcinoma | C | ||||
| LAN-1 | Human | Neuroblastoma | C | C | |||
| NMB | Human | Neuroblastoma | C | C | |||
|
| |||||||
| Not determined | CHO clone 1 | Chinese hamster | Ovary | C | C | C | |
| CHO clone 2 | Chinese hamster | Ovary | C | C | C | ||
| JW-8 | Mouse | Hybridoma | C | C | C | ||
| U-266 | Human | Leukemia | C | C | C | ||
Outcome of treatment: C: cured; D: dead; R: resistant; →: back-up (untreated) mycoplasma-positive cells were treated in a second attempt.
AB: antibiotics (as indicated in table); cell lines 1-6: cell lines received for elimination of mycoplasma as service.